Clinical Trial Update: Residual IDH1-Mutant Tumor Cell Quantification Study [NA]

View source ↗

Summary

Clinical trial update for a study on quantifying residual IDH1-mutant tumor cells in glioma, sponsored by NYU Langone Health, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Snippet

Sponsor: NYU Langone Health | Conditions: Glioma | NA | Status: NOT_YET_RECRUITING